Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Toward more accurate preclinical glioblastoma modeling: Reverse translation of clinical standard of care in a glioblastoma mouse model.
Methods Cell Biol. 2024;183:381-397. doi: 10.1016/bs.mcb.2023.07.003. Epub 2023 Sep 15.
Methods Cell Biol. 2024.
PMID: 38548420
TIM3 Checkpoint Inhibition Fails to Prolong Survival in Ovarian Cancer-Bearing Mice.
Berckmans Y, Vankerckhoven A, Caro AA, Kempeneers J, Ceusters J, Thirion G, Vandenbrande K, Vergote I, Laoui D, Coosemans A.
Berckmans Y, et al.
Cancers (Basel). 2024 Mar 14;16(6):1147. doi: 10.3390/cancers16061147.
Cancers (Basel). 2024.
PMID: 38539483
Free PMC article.
Item in Clipboard
Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy.
Berckmans Y, Ceusters J, Vankerckhoven A, Wouters R, Riva M, Coosemans A.
Berckmans Y, et al.
Front Immunol. 2023 Sep 7;14:1236965. doi: 10.3389/fimmu.2023.1236965. eCollection 2023.
Front Immunol. 2023.
PMID: 37744323
Free PMC article.
Review.
Item in Clipboard
Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates.
Berckmans Y, Hoffert Y, Vankerckhoven A, Dreesen E, Coosemans A.
Berckmans Y, et al.
Pharmaceutics. 2023 Jun 22;15(7):1792. doi: 10.3390/pharmaceutics15071792.
Pharmaceutics. 2023.
PMID: 37513979
Free PMC article.
Review.
Item in Clipboard
Intraperitoneal alpha therapy with 224Ra-labeled microparticles combined with chemotherapy in an ovarian cancer mouse model.
Wouters R, Westrøm S, Berckmans Y, Riva M, Ceusters J, Bønsdorff TB, Vergote I, Coosemans A.
Wouters R, et al. Among authors: berckmans y.
Front Med (Lausanne). 2022 Oct 10;9:995325. doi: 10.3389/fmed.2022.995325. eCollection 2022.
Front Med (Lausanne). 2022.
PMID: 36300186
Free PMC article.
Item in Clipboard
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer.
Sprooten J, Vankerckhoven A, Vanmeerbeek I, Borras DM, Berckmans Y, Wouters R, Laureano RS, Baert T, Boon L, Landolfo C, Testa AC, Fischerova D, Van Holsbeke C, Bourne T, Chiappa V, Froyman W, Schols D, Agostinis P, Timmerman D, Tejpar S, Vergote I, Coosemans A, Garg AD.
Sprooten J, et al. Among authors: berckmans y.
J Immunother Cancer. 2021 Nov;9(11):e003609. doi: 10.1136/jitc-2021-003609.
J Immunother Cancer. 2021.
PMID: 34795003
Free PMC article.
Item in Clipboard
Cite
Cite